(0.37%) 5 118.97 points
(0.29%) 38 351 points
(0.39%) 15 990 points
(-1.10%) $82.93
(3.48%) $1.990
(-0.01%) $2 347.00
(0.04%) $27.55
(3.19%) $951.55
(-0.03%) $0.934
(-0.05%) $11.02
(-0.28%) $0.798
(1.84%) $93.56
3 days till quarter result
(bmo 2024-05-02)
Expected move: +/- 11.09%
Live Chart Being Loaded With Signals
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology...
Stats | |
---|---|
Šios dienos apimtis | 163 755 |
Vidutinė apimtis | 2.85M |
Rinkos kapitalizacija | 3.23B |
EPS | $0 ( 2024-02-22 ) |
Kita pelno data | ( $0.740 ) 2024-05-02 |
Last Dividend | $1.000 ( 2010-11-10 ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.46 |
ATR14 | $0.0130 (0.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-29 | Paulson John | Buy | 5 890 | Common Shares, No Par Value |
2024-03-29 | Icahn Brett | Buy | 3 122 | Common Shares, No Par Value |
2024-03-29 | Robertson Russel C | Buy | 2 945 | Common Shares, No Par Value |
2024-03-29 | Wechsler Amy B | Buy | 647 | Common Shares, No Par Value |
2024-02-29 | Barresi John S | Buy | 39 126 | Common Shares, No Par Value |
INSIDER POWER |
---|
67.94 |
Last 100 transactions |
Buy: 2 132 507 | Sell: 336 154 |
Tūris Koreliacija
Bausch Health Companies Koreliacija
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Bausch Health Companies Koreliacija - Valiuta/Žaliavos
Bausch Health Companies Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $8.76B |
Bruto pelnas: | $6.20B (70.78 %) |
EPS: | $-1.620 |
FY | 2023 |
Pajamos: | $8.76B |
Bruto pelnas: | $6.20B (70.78 %) |
EPS: | $-1.620 |
FY | 2022 |
Pajamos: | $8.12B |
Bruto pelnas: | $5.76B (70.90 %) |
EPS: | $-0.590 |
FY | 2021 |
Pajamos: | $8.43B |
Bruto pelnas: | $6.04B (71.61 %) |
EPS: | $-2.67 |
Financial Reports:
No articles found.
Bausch Health Companies Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.500 | 2005-11-28 |
Last Dividend | $1.000 | 2010-11-10 |
Next Dividend | $0 | N/A |
Payout Date | 2010-12-22 | |
Next Payout Date | N/A | |
# dividends | 22 | -- |
Total Paid Out | $6.43 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.06 | -- |
Div. Sustainability Score | 6.11 | |
Div.Growth Potential Score | 2.84 | |
Div. Directional Score | 4.48 | -- |
Year | Amount | Yield |
---|---|---|
2005 | $0.500 | 3.07% |
2006 | $0.500 | 2.01% |
2007 | $2.00 | 9.47% |
2008 | $1.500 | 11.20% |
2009 | $0.645 | 6.68% |
2010 | $1.280 | 8.72% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
VGI | Dividend Royal | 2024-02-09 | Monthly | 13 | 7.36% | 8.50 |
JQC | Dividend Royal | 2023-11-14 | Monthly | 22 | 6.56% | 8.50 |
PHK | Dividend Royal | 2023-11-10 | Monthly | 22 | 6.88% | 8.50 |
PCF | Dividend King | 2023-12-18 | Monthly | 38 | 7.05% | 8.50 |
PVL | Dividend King | 2023-11-15 | Monthly | 14 | 9.37% | 8.50 |
NCV | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.68% | 8.50 |
SBR | Dividend Royal | 2023-11-14 | Monthly | 38 | 7.74% | 8.50 |
MTR | Dividend Diamond | 2023-10-30 | Monthly | 39 | 10.10% | 8.50 |
PDI | Dividend Royal | 2023-11-10 | Monthly | 13 | 7.86% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.0190 | 1.500 | -0.379 | -0.569 | [0 - 0.5] |
returnOnAssetsTTM | -0.00607 | 1.200 | -0.202 | -0.243 | [0 - 0.3] |
returnOnEquityTTM | 0.171 | 1.500 | 9.21 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.301 | 0.800 | 8.50 | 6.80 | [1 - 3] |
quickRatioTTM | 0.685 | 0.800 | -0.679 | -0.543 | [0.8 - 2.5] |
cashRatioTTM | 0.220 | 1.500 | 9.89 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.819 | -1.500 | 10.00 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -0.725 | 1.000 | -1.380 | -1.380 | [3 - 30] |
operatingCashFlowPerShareTTM | 3.00 | 2.00 | 9.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 2.23 | 2.00 | 8.89 | 10.00 | [0 - 20] |
debtEquityRatioTTM | -21.91 | -1.500 | -10.00 | 10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.995 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.110 | 1.000 | 9.80 | 9.80 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.0489 | 1.000 | -0.839 | -0.839 | [0.2 - 2] |
assetTurnoverTTM | 0.320 | 0.800 | -1.199 | -0.959 | [0.5 - 2] |
Total Score | 6.11 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -19.16 | 1.000 | -2.04 | 0 | [1 - 100] |
returnOnEquityTTM | 0.171 | 2.50 | 9.49 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 2.23 | 2.00 | 9.26 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 3.00 | 2.00 | 9.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.390 | 1.500 | -5.93 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.125 | 1.000 | 9.37 | 0 | [0.1 - 0.5] |
Total Score | 2.84 |
Bausch Health Companies
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.